文献速递脑血管病神经重症与神经感染

甲氧氯普胺预防卒中并鼻胃管患者肺炎:PRECIOUS试验数据

Metoclopramide to Prevent Pneumonia in Patients With Stroke and a Nasogastric Tube: Data From the PRECIOUS Trial.
PubMed 文献 · Stroke · 2024-08-12

PRECIOUS试验的事后分析纳入1376例急性卒中患者,其中随机后首日329例(23.9%)置有鼻胃管,156例分配至甲氧氯普胺组、173例标准治疗组。甲氧氯普胺10 mg每日三次用4天未降低肺炎风险(41.0% vs 35.8%,调整OR 1.35,95%CI 0.79-2.30),对90天功能结局也无影响(调整OR 1.07,95%CI 0.71-1.61)。

要点

  • 急性卒中置鼻胃管患者中,甲氧氯普胺未降低首周肺炎风险。
  • 甲氧氯普胺组肺炎41.0% vs 标准治疗组35.8%,调整OR 1.35(95%CI 0.79-2.30)。
  • 甲氧氯普胺对90天改良Rankin量表评分无影响,调整OR 1.07(95%CI 0.71-1.61)。

核心结论

  • 卒中发病后不久置鼻胃管的患者中,甲氧氯普胺用4天未降低肺炎风险,对功能结局也无影响。

研究设计与样本

  • PRECIOUS为国际、3×2部分析因、随机对照、开放标签、结局评估盲法的临床试验,评估甲氧氯普胺、对乙酰氨基酚和头孢曲松的预防治疗。
  • 纳入年龄≥66岁、急性缺血性卒中或脑出血且美国国立卫生研究院卒中量表评分≥6分的患者。
  • 本分析纳入随机后24小时内置鼻胃管的患者,比较分配至甲氧氯普胺(10 mg每日三次)者与未分配者。
  • 治疗在症状发作后24小时内开始,持续4天,若提前出院则至出院。
  • 2016年4月至2022年6月共入选1493例,1376例纳入本分析,其中1185例(86%)为缺血性卒中、191例(14%)为脑出血。

主要发现

  • 随机后首日329例(23.9%)置有鼻胃管,其中156例分配至甲氧氯普胺、173例分配至标准治疗。
  • 甲氧氯普胺与肺炎风险降低无关:甲氧氯普胺组41.0% vs 标准治疗组35.8%,调整OR 1.35(95%CI 0.79-2.30)。
  • 甲氧氯普胺与不良功能结局无关:调整OR 1.07(95%CI 0.71-1.61)。

关键数值与推荐

  • 主要结局为卒中后首周肺炎。
  • 次要结局为90天后改良Rankin量表评分,采用序数logistic回归分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A randomized trial suggested that treatment with metoclopramide reduces the risk of pneumonia in patients with acute stroke and a nasogastric tube. We assessed whether this finding could be replicated in a post hoc analysis of the randomized PRECIOUS trial (Prevention of Complications to Improve Outcome in Elderly Patients With Acute Stroke). METHODS: PRECIOUS was an international, 3×2 partial-factorial, randomized controlled, open-label clinical trial with blinded outcome assessment assessing preventive treatment with metoclopramide, paracetamol, and ceftriaxone in patients aged ≥66 years with acute ischemic stroke or intracerebral hemorrhage and a National Institutes of Health Stroke Scale score ≥6. In the present study, we analyzed patients who had a nasogastric tube within 24 hours after randomization. Patients who were allocated to metoclopramide (10 mg TID) were compared with patients who were not. Treatment was started within 24 hours after symptom onset and continued for 4 days or until discharge if earlier. The primary outcome was pneumonia in the first week after stroke. The score on the modified Rankin Scale after 90 days was a secondary outcome and analyzed with ordinal logistic regression. RESULTS: From April 2016 through June 2022, a total of 1493 patients were enrolled with 1376 included in this analysis, of whom 1185 (86%) had ischemic stroke and 191 (14%) had intracerebral hemorrhage. The first day after randomization, 329 (23.9%) patients had a nasogastric tube, of whom 156 were allocated to metoclopramide and 173 to standard care. Metoclopramide was not associated with a reduction of pneumonia (41.0% versus 35.8%; adjusted odds ratio, 1.35 [95% CI, 0.79-2.30]) or with poor functional outcome (adjusted odds ratio, 1.07 [95% CI, 0.71-1.61]). CONCLUSIONS: In patients with stroke who had a nasogastric tube shortly after stroke onset, metoclopramide for 4 days did not reduce pneumonia or have an effect on the functional outcome.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Sluis WM, de Jonge JC, Reinink H, et al. Metoclopramide to Prevent Pneumonia in Patients With Stroke and a Nasogastric Tube: Data From the PRECIOUS Trial. Stroke. 2024. PMID: 39129650. doi:10.1161/STROKEAHA.124.047582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。